2100 Powell Street
About Dynavax Technologies
We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.
396 articles with Dynavax Technologies
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
Dynavax Donates 10,000 Doses of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amidst COVID-19 Pandemic
The U.S. FDA approved vaccine is being provided to help protect critical healthcare workers in emergency medical settings from hepatitis B infections
Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
Dynavax to provide CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of COVID-19 vaccines
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) EMERYVILLE, Calif. and CHENGDU, China, March 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceut
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine
Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine
Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11
EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report fourth quarter and full year 2019 financial results on Wednesday, March 11, 2020, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, March 11, 2019 at 4:30 p.m. (ET)/1:30 p.m. (PT). The live audio webcast may be accessed through
Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of DirectorsDavid Novack Appointed President and Chief Operating Officer
These appointments are effective December 16, 2019.
Similar rates of acute myocardial infarction between the two treatment arms at the interim analysis reinforces the view that HEPLISAV-B has the potential to be the leading hepatitis B vaccine for adults
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported financial results for the third quarter ended September 30, 2019.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Hundreds lose their jobs as companies close facilities and shift business focuses.
Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.
Asthma drug failed to show a statistically clinical improvement in controlling asthma, Dynavax said.
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Feb. 5, 2018
These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.85 per share.
Dynavax Announces HEPLISAV-B is Now Available in the United States for the Prevention of Hepatitis B in Adults
HEPLISAV-B can now be ordered through a network of distributors, which will broaden over the next few weeks.
Dynavax granted stock options to purchase shares of Dynavax's common stock to the new employees with an exercise price of $18.40 per share.
The FDA approved Dynavax's Heplisav-B, it's first new hepatitis B vaccine in the U.S. in more than 25 years.